Caladrius Biosciences has entered into an agreement with SPS Cardio to out-license the patent and commercialization rights for the company’s CD34 ischemic repair technology in select territories outside of the U.S.
SPS will fund the further development of this technology and will conduct a phase 2 proof-of-concept clinical trial in India to evaluate CD34 cell therapy for the prevention of adverse events in patients with heart failure. SPS will receive an exclusive license to the CD34 cell therapy technology for use in acute myocardial infarction and chronic heart failure in India and in other territories outside the U.S.
“We are pleased to out-license our CD34 technology in AMI and CHF to SPS as it is in keeping with our strategic focus to build on our core competency in cell therapy process development and manufacturing. This agreement allows us to preserve capital, while retaining our ability to enter into separate development and commercialization partnerships for other indications and in other territories, such as for critical limb ischemia in Japan,” – David J. Mazzo, PhD., CEO of Caladrius.
Source: Caladrius Biosciences Out-licenses CD34 Technology to SPS Cardio, LLC for Chronic Heart Failure and Acute Myocardial Infarction;Press Release